The diagnosis of CLL/SLL relies on flow cytometric immunophenotyping. Increasing emphasis is being placed on precise detection of the minimal residual disease. Following antigen recommendations of ERIC and ESCCA's Harmonization Project, we validated a 14-color assay for the characterization CD5+ lymphoproliferative neoplasms and CLL MRD with a sensitivity of at least 10⁻⁴.

中文翻译：

---

14 色单管，用于 CD5+ B-LPD 的流式细胞仪表征和 CLL/SLL 的高灵敏度自动化最小残留疾病定量

CLL/SLL 的诊断依赖于流式细胞仪免疫表型分析。越来越重视对微小残留病的精确检测。根据 ERIC 和 ESCCA 协调项目的抗原建议，我们验证了用于表征 CD5+ 淋巴组织增生性肿瘤和 CLL MRD 的 14 色检测方法，其灵敏度至少为 10 ^-4。